Starpharma Holdings Limited (SPL.AX)
-ASX 0.84 
0.01(0.60%) May 17, 2:10AM EDT
| Prev Close: | 0.84 |
|---|
| Open: | 0.85 |
|---|
| Bid: | 0.84 |
|---|
| Ask: | 0.87 |
|---|
| 1y Target Est: | 1.79 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.83 - 0.88 |
|---|
| 52wk Range: | 0.83 - 1.75 |
|---|
| Volume: | 1,843,392 |
|---|
| Avg Vol (3m): | 450,443 |
|---|
| Market Cap: | 238.26M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in AUD.
Headlines
- Appendix 4C - Quarterly Cashflow Reportat Reuters(Tue, Apr 23)
- Starpharma Granted New Drug Delivery Patentsat Reuters(Tue, Apr 16)
- Form 604 - Notice of change of interests of substantial holderat Reuters(Sun, Apr 7)
- Change of Director's Interest Notice - Zita Peachat Reuters(Sun, Apr 7)
- VivaGel phase 2 study results - investor conference callat Reuters(Wed, Apr 3)
- Trading Haltat Reuters(Mon, Apr 1)
- Starpharma and Makhteshim Agan in Priostar Agrochemical CollaborationPR Newswire(Wed, Mar 13)
- Dendrimers improve efficacy in lung metastasis modelat Reuters(Sun, Mar 3)
- Appendix 3Bat Reuters(Wed, Jan 16)
- Shareholder Update: December 2012at Reuters(Tue, Dec 18)
- Change of Director's Interest Notice - J Fairleyat Reuters(Mon, Dec 17)
- Appendix 3Bat Reuters(Mon, Dec 17)
- Starpharma appoints experienced Business Development VPat Reuters(Sun, Dec 16)
- Change of Director's Interest Notice - Peter Bartelsat Reuters(Wed, Dec 12)
- Form 604 Notice of change of interests of substantial holderat Reuters(Mon, Dec 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 79.29 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.04 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Starpharma Holdings Limited, together with its subsidiaries, engages in the development and commercialization of dendrimer products for pharmaceutical, life science, and other applications primarily in the United States and Australia.
View More